Advanced Unbiased Proteomics for Translational Discovery

Unbiased proteomics enables the identification of biomarkers, pathways, and mechanistic signatures without predefined targets. By taking a label-free, discovery-driven approach, researchers can uncover novel biology and drug targets directly from complex biological samples. 

CellCarta’s unbiased proteomics platform delivers comprehensive protein coverage, capturing thousands of proteins and post-translational modifications (PTMs) across diverse biological matrices without prior target selection.  

Our workflows are designed to generate reliable, high-quality data suitable for translational and clinical research environments. 

Through advanced proteomic technologies and expertise across cell, tissue, and biopsy samples, we enable robust, unbiased discovery.

High-resolution liquid chromatography-mass spectrometry (MS)/MS

Our LC–MS/MS workflows are powered by cutting-edge instrumentation and support sensitive, in-depth proteome profiling.  

Data analysis is conducted by our dedicated bioinformatics team using standardized pipelines designed for reproducibility and traceability. As a CRO, we generate high-quality, regulatory-ready datasets suitable for translational and clinical research environments.

Olink® Reveal

CellCarta offers the Olink® Reveal platform for high-sensitivity measurement of ~1000 predefined protein targets. Complementary to LC–MS/MS, Olink Reveal enables focused, high-depth analysis of established targets and can serve as an alternative discovery strategy when study objectives are centered on predefined panels. 

Key advantages of Olink include: 

• Minimal sample volume requirements (as low as 1 µL of blood) 
• High sensitivity and specificity  
• Broad dynamic range

Characterizing naturally presented MHC-bound peptides (the immunopeptidome) is essential for understanding antigen presentation and immune recognition. While computational algorithms are often used to predict which peptides may bind to MHC molecules, predicted candidates do not always reflect what is actually presented in tissue. Direct measurement of the immunopeptidome is therefore essential for physiologically relevant insight.  

To enable scalable and reproducible analysis, CellCarta has developed a ​high-throughput workflow for the identification of naturally presented MHC-bound peptides. By automating the immunoaffinity enrichment step using a KingFisher magnetic particle processor, we reduce manual variability and enable consistent, large-cohort processing. 

To support target prioritization, our ​​Antigen Atlas database provides a curated reference of MHC class I–presented peptides identified across healthy and tumor-adjacent tissues, enabling thorough assessment of tissue specificity and potential on-target/off-tissue effects.  

Key applications of our MHC peptide workflow include:  

• Neoantigen discovery for cancer immunotherapy
• Vaccine and therapeutic design
• Autoimmune and infectious disease research

Our teams bring technical expertise and operational rigor to support unbiased proteomic research, offering:  

• Integrated translational insight: connect discovery proteomics to downstream verification, targeted assay development, and biological interpretation, all within CellCarta. 
• End-to-end support: from sample preparation and LC–MS/MS analysis to bioinformatics and reporting, we can provide support for the full workflow.
• A strong quality and compliance focus: our standardized workflows and procedures align with industry best practices to ensure reproducible, high-confidence data.
• Global coverage: with CAP-accredited and CLIA-certified labs in Canada, USA, Belgium, Australia, and China, you can ensure harmonized workflows and expert support for multi-site and international research programs.

Want to find out more about how we can support your unbiased proteomic discovery?